SynthesisPloS one2017
The full benefits of adult pneumococcal vaccination: A systematic review.
Synthesis in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Effectiveness of pneumococcal vaccination in reducing hospitalization and mortality among the elderly: A systematic review and meta-analysis.Human vaccines & immunotherapeutics · 2025Pooled it
- The Value(s) of Vaccination: Building the Scientific Evidence According to a Value-Based Healthcare Approach.Frontiers in public health · 2022Pooled it
- Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions.PharmacoEconomics · 2019Pooled it
- Trends in Hospitalization, Case Fatality, and Mortality for Community-Acquired Pneumonia in Portugal over 20 Years.Epidemiologia (Basel, Switzerland) · 2026Article
- Life Course Vaccination Continuum (LCVAC): An Expert Consensus on Life Course Vaccination in India.Cureus · 2026Review
- Taxonomy of the Full Health and Societal Value of Maternal Vaccination to Prevent Infant Respiratory Syncytial Virus Disease.Infectious diseases and therapy · 2026Review
- Cost-effectiveness and return on investment of 20-valent pneumococcal conjugate vaccine use among adults in England: analysis from the societal perspective.Cost effectiveness and resource allocation : C/E · 2026Article
- Conceptual Methodological Framework for Incorporating Antimicrobial Resistance Considerations in Economic Models for Pneumococcal Conjugate Vaccines.Infectious diseases and therapy · 2025Article
- Health care resource use and costs associated with adult pneumococcal disease in the United States from 2017 to 2019, stratified by age and health risk: a retrospective cohort study.Frontiers in public health · 2025Article
- A Structured Narrative Literature Review of the Broader Value of Adult Immunisation Programmes.Vaccines · 2024Review
- Article
- Impact of industry sponsorship on the quality of systematic reviews of vaccines: a cross-sectional analysis of studies published from 2016 to 2019.Systematic reviews · 2022Article
- A global agenda for older adult immunization in the COVID-19 era: A roadmap for action.Vaccine · 2021Article
- Pneumonia and Invasive Pneumococcal Diseases: The Role of Pneumococcal Conjugate Vaccine in the Era of Multi-Drug Resistance.Vaccines · 2021Review
- Article
- SLy2-deficiency promotes B-1 cell immunity and triggers enhanced production of IgM and IgGImmunity, inflammation and disease · 2020Article
- [Pneumococcal vaccine for adults over 65].Atencion primaria · 2020Article
- Clinical and financial burden of hospitalised community-acquired pneumonia in patients with selected underlying comorbidities in England.BMJ open respiratory research · 2020Article
- Clinical practice guidelines 2019: Indian consensus-based recommendations on pneumococcal vaccination for adults.Lung India : official organ of Indian Chest Society · 2020Article
- Assessment of Health Care Exposures and Outcomes in Adult Patients With Sepsis and Septic Shock.JAMA network open · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPneumococcal disease causes substantial morbidity and mortality, including among adults. Adult pneumococcal vaccines help to prevent these burdens, but they are underused. Accounting for the full benefits of adult pneumococcal vaccination may promote more rational resource allocation decisions with respect to adult pneumococcal vaccines.
objectivesUsing the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we conducted a systematic review to assess the extent to which the literature has empirically captured (e.g., through measurement or modeling) the full benefits of adult pneumococcal vaccination.
methodsWe systematically searched PubMed and Embase to identify studies published between January 1, 2010 and April 10, 2016 that examine adult pneumococcal vaccination. We included articles if they captured any health or economic benefit of an adult pneumococcal vaccine administered to adults age ≥ 50 or ≥ 18 in risk groups. Finally, we summarized the literature by categorizing the types of benefits captured, the perspective taken, and the strength of the evidence presented. Our protocol is number 42016038335 in the PROSPERO International prospective register of systematic reviews.
resultsWe identified 5,857 papers and included 150 studies for analysis. While most capture health gains and healthcare cost savings, far fewer studies consider additional benefit categories, such as productivity gains. However, the studies with a broader approach still exhibit significant limitations; for example, many present only abstracts, while others offer no new measurements. Studies that examine the 13-valent pneumococcal conjugate vaccine focus more on broad economic benefits, but still have limitations.
conclusionsThis review highlights the need for more robust empirical accounting of the full benefits of adult pneumococcal vaccination. Literature outside this realm indicates that these broad benefits may be substantial. Failing to investigate the full benefits may lead society to undervalue vaccines' contributions and therefore underinvest in their development and adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.